Tag: subsidiary

As Managing Director, Sanford will guide the evolution of SUCCESS+ with cutting-edge AI tools designed to elevate personal growth, performance, and impact

VANCOUVER, British Columbia, July 29, 2025 (GLOBE NEWSWIRE) -- ZenaTech, Inc. (Nasdaq: ZENA) (FSE: 49Q) (BMV: ZENA) ("ZenaTech"), a business technology solution provider specializing in AI (Artificial Intelligence) drones, Drone as a Service (DaaS), Enterprise SaaS, and Quantum Computing solutions, today announces the formation of Zena AI, Inc. (Zena AI), an AI Development Center part of its ZenaDrone US drone company subsidiary. Zena AI will be focused on building advanced artificial intelligence software solutions for the US Department of Defense and Homeland Security agencies. The announcement comes in response to the White House’s AI Action Plan and related Executive Orders released on July 23^rd that set a nationwide agenda for accelerating American-made AI systems across federal and defense sectors and boosting global exports.

SEOUL, South Korea, July 29, 2025 (GLOBE NEWSWIRE) -- DoubleDown Interactive Co., Ltd. (NASDAQ: DDI) (“DoubleDown” or the “Company”), a leading developer and publisher of digital games on mobile and web-based platforms, announced today that it will release its 2025 second quarter financial results after the market closes on Tuesday, August 12, 2025, and host a conference call and simultaneous webcast at 5:00 p.m. ET (2:00 p.m. PT) that day. Both the call and webcast are open to the general public. On the call, DoubleDown management will review the Company’s financial results and provide a business update, followed by a question-and-answer session.

Zurich, July 29, 2025 – MetrioPharm AG, a pharmaceutical company developing drugs for inflammatory and infectious diseases, announced today that the European Medicines Agency has granted Orphan Drug Designation (ODD) to its lead compound, MP1032 for the treatment of children affected by Duchenne muscular dystrophy (DMD). This milestone follows the U.S. FDA's ODD, underscoring MP1032's potential as a first-in-class therapy that could minimize reliance on high-dose corticosteroids, which cause severe side effects like osteoporosis, growth stunting, and metabolic issues.

Presented at Taiwan Healthy Ageing Tech Show in August Showcasing Senior Vision Care Innovation

Press release
Paris, 29 July 2025